Literature DB >> 21696834

Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia.

Michael Ewers1, Reisa A Sperling, William E Klunk, Michael W Weiner, Harald Hampel.   

Abstract

Alzheimer's disease (AD) is a progressive age-related neurodegenerative disease. At the time of clinical manifestation of dementia, significant irreversible brain damage is already present, rendering the diagnosis of AD at early stages of the disease an urgent prerequisite for therapeutic treatment to halt, or at least slow, disease progression. In this review, we discuss various neuroimaging measures that are proving to have potential value as biomarkers of AD pathology for the detection and prediction of AD before the onset of dementia. Recent studies that have identified AD-like structural and functional brain changes in elderly people who are cognitively within the normal range or who have mild cognitive impairment (MCI) are discussed. A dynamic sequence model of changes that occur in neuroimaging markers during the different disease stages is presented and the predictive value of multimodal neuroimaging for AD dementia is considered. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21696834      PMCID: PMC3275347          DOI: 10.1016/j.tins.2011.05.005

Source DB:  PubMed          Journal:  Trends Neurosci        ISSN: 0166-2236            Impact factor:   13.837


  122 in total

1.  Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects.

Authors:  E C Mormino; J T Kluth; C M Madison; G D Rabinovici; S L Baker; B L Miller; R A Koeppe; C A Mathis; M W Weiner; W J Jagust
Journal:  Brain       Date:  2008-11-28       Impact factor: 13.501

2.  The Clinical Dementia Rating (CDR): current version and scoring rules.

Authors:  J C Morris
Journal:  Neurology       Date:  1993-11       Impact factor: 9.910

Review 3.  Brain 18F-FDG PET in the diagnosis of neurodegenerative dementias: comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging.

Authors:  Daniel H S Silverman
Journal:  J Nucl Med       Date:  2004-04       Impact factor: 10.057

4.  Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.

Authors:  G McKhann; D Drachman; M Folstein; R Katzman; D Price; E M Stadlan
Journal:  Neurology       Date:  1984-07       Impact factor: 9.910

Review 5.  Neurodegeneration in normal brain aging and disease.

Authors:  Dietmar Rudolf Thal; Kelly Del Tredici; Heiko Braak
Journal:  Sci Aging Knowledge Environ       Date:  2004-06-09

6.  Age-specific incidence of Alzheimer's disease in a community population.

Authors:  L E Hebert; P A Scherr; L A Beckett; M S Albert; D M Pilgrim; M J Chown; H H Funkenstein; D A Evans
Journal:  JAMA       Date:  1995-05-03       Impact factor: 56.272

7.  Outcome in subgroups of mild cognitive impairment (MCI) is highly predictable using a simple algorithm.

Authors:  Joanna Mitchell; Robert Arnold; Kate Dawson; Peter J Nestor; John R Hodges
Journal:  J Neurol       Date:  2009-05-12       Impact factor: 4.849

8.  Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E.

Authors:  E M Reiman; R J Caselli; L S Yun; K Chen; D Bandy; S Minoshima; S N Thibodeau; D Osborne
Journal:  N Engl J Med       Date:  1996-03-21       Impact factor: 91.245

9.  Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease.

Authors:  G W Small; J C Mazziotta; M T Collins; L R Baxter; M E Phelps; M A Mandelkern; A Kaplan; A La Rue; C F Adamson; L Chang
Journal:  JAMA       Date:  1995 Mar 22-29       Impact factor: 56.272

10.  Neural correlates of Alzheimer's disease and mild cognitive impairment: a systematic and quantitative meta-analysis involving 1351 patients.

Authors:  Matthias L Schroeter; Timo Stein; Nina Maslowski; Jane Neumann
Journal:  Neuroimage       Date:  2009-05-20       Impact factor: 6.556

View more
  116 in total

Review 1.  Translational research in neurology: dementia.

Authors:  Lawrence S Honig
Journal:  Arch Neurol       Date:  2012-08

Review 2.  Molecular brain imaging in the multimodality era.

Authors:  Julie C Price
Journal:  J Cereb Blood Flow Metab       Date:  2012-03-21       Impact factor: 6.200

3.  Selective GABA(A) α5 positive allosteric modulators improve cognitive function in aged rats with memory impairment.

Authors:  Ming Teng Koh; Sharon Rosenzweig-Lipson; Michela Gallagher
Journal:  Neuropharmacology       Date:  2012-06-23       Impact factor: 5.250

4.  Aging-Related Hyperexcitability in CA3 Pyramidal Neurons Is Mediated by Enhanced A-Type K+ Channel Function and Expression.

Authors:  Dina Simkin; Shoai Hattori; Natividad Ybarra; Timothy F Musial; Eric W Buss; Hannah Richter; M Matthew Oh; Daniel A Nicholson; John F Disterhoft
Journal:  J Neurosci       Date:  2015-09-23       Impact factor: 6.167

5.  Mapping 3-year changes in gray matter and metabolism in Aβ-positive nondemented subjects.

Authors:  Miguel Ángel Araque Caballero; Matthias Brendel; Andreas Delker; Jinyi Ren; Axel Rominger; Peter Bartenstein; Martin Dichgans; Michael W Weiner; Michael Ewers
Journal:  Neurobiol Aging       Date:  2015-08-18       Impact factor: 4.673

6.  The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations.

Authors:  E Cavedo; S Lista; Z Khachaturian; P Aisen; P Amouyel; K Herholz; C R Jack; R Sperling; J Cummings; K Blennow; S O'Bryant; G B Frisoni; A Khachaturian; M Kivipelto; W Klunk; K Broich; S Andrieu; M Thiebaut de Schotten; J-F Mangin; A A Lammertsma; K Johnson; S Teipel; A Drzezga; A Bokde; O Colliot; H Bakardjian; H Zetterberg; B Dubois; B Vellas; L S Schneider; H Hampel
Journal:  J Prev Alzheimers Dis       Date:  2014-12

Review 7.  DSM-5 reviewed from different angles: goal attainment, rationality, use of evidence, consequences—part 2: bipolar disorders, schizophrenia spectrum disorders, anxiety disorders, obsessive-compulsive disorders, trauma- and stressor-related disorders, personality disorders, substance-related and addictive disorders, neurocognitive disorders.

Authors:  Hans-Jürgen Möller; Borwin Bandelow; Michael Bauer; Harald Hampel; Sabine C Herpertz; Michael Soyka; Utako B Barnikol; Simone Lista; Emanuel Severus; Wolfgang Maier
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-08-26       Impact factor: 5.270

Review 8.  Perturbations of neural circuitry in aging, mild cognitive impairment, and Alzheimer's disease.

Authors:  Stephanie L Leal; Michael A Yassa
Journal:  Ageing Res Rev       Date:  2013-02-04       Impact factor: 10.895

9.  Emotion-related brain organization and behavioral responses to socioemotional stimuli in pediatric cancer survivors with posttraumatic stress symptoms.

Authors:  Hilary A Marusak; Allesandra S Iadipaolo; Shelley Paulisin; Felicity W Harper; Jeffrey W Taub; Kristopher Dulay; Farrah Elrahal; Craig Peters; Kelsey Sala-Hamrick; Laura M Crespo; Christine A Rabinak
Journal:  Pediatr Blood Cancer       Date:  2018-09-30       Impact factor: 3.167

10.  The fornix provides multiple biomarkers to characterize circuit disruption in a mouse model of Alzheimer's disease.

Authors:  Alexandra Badea; Lauren Kane; Robert J Anderson; Yi Qi; Mark Foster; Gary P Cofer; Neil Medvitz; Anne F Buckley; Andreas K Badea; William C Wetsel; Carol A Colton
Journal:  Neuroimage       Date:  2016-08-10       Impact factor: 6.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.